NASDAQ:ASND
$116.10
(
-1.39%
)
Friday, 3rd Feb 2023
Ascendis Pharma A/S Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $107.74 | $127.77 | Friday, 3rd Feb 2023 ASND stock ended at $116.10. This is 1.39% less than the trading day before Thursday, 2nd Feb 2023. During the day the stock fluctuated 3.82% from a day low at $115.08 to a day high of $119.48. |
| 90 days | $107.74 | $134.53 | |
| 52 weeks | $61.58 | $134.53 |
Historical Ascendis Pharma A/S prices
| Date | Open | High | Low | Close | Volume |
| 2023-02-03 | $116.89 | $119.48 | $115.08 | $116.10 | 126 947 |
| 2023-02-02 | $124.22 | $124.65 | $116.49 | $117.74 | 276 550 |
| 2023-02-01 | $125.01 | $125.18 | $120.05 | $123.50 | 156 596 |
| 2023-01-31 | $120.74 | $124.29 | $120.74 | $124.08 | 141 200 |
| 2023-01-30 | $122.50 | $123.50 | $120.00 | $120.80 | 359 051 |
| 2023-01-27 | $121.50 | $124.38 | $118.01 | $122.50 | 153 978 |
| 2023-01-26 | $121.06 | $122.59 | $119.22 | $121.53 | 119 870 |
| 2023-01-25 | $120.70 | $122.00 | $118.31 | $119.90 | 142 433 |
| 2023-01-24 | $123.42 | $124.65 | $120.69 | $122.39 | 460 675 |
| 2023-01-23 | $122.83 | $124.29 | $120.66 | $123.79 | 234 409 |
| 2023-01-20 | $122.48 | $124.31 | $121.39 | $123.02 | 236 600 |
| 2023-01-19 | $120.08 | $121.72 | $117.31 | $121.51 | 302 000 |
| 2023-01-18 | $119.81 | $123.15 | $118.92 | $119.86 | 282 400 |
| 2023-01-17 | $115.00 | $122.15 | $114.88 | $119.65 | 219 731 |
| 2023-01-13 | $117.71 | $120.85 | $115.03 | $115.03 | 385 167 |
| 2023-01-12 | $114.17 | $119.44 | $113.80 | $117.91 | 370 817 |
| 2023-01-11 | $113.54 | $117.12 | $111.63 | $113.64 | 353 105 |
| 2023-01-10 | $108.07 | $113.08 | $108.07 | $112.61 | 385 100 |
| 2023-01-09 | $126.40 | $126.40 | $107.74 | $109.27 | 845 316 |
| 2023-01-06 | $125.43 | $127.77 | $122.70 | $126.78 | 218 200 |
| 2023-01-05 | $121.46 | $125.03 | $118.73 | $124.20 | 198 743 |
| 2023-01-04 | $122.48 | $123.19 | $118.96 | $122.08 | 340 223 |
| 2023-01-03 | $125.23 | $125.23 | $118.10 | $120.72 | 264 904 |
| 2022-12-30 | $120.21 | $122.98 | $119.06 | $122.13 | 175 268 |
| 2022-12-29 | $118.00 | $123.85 | $117.09 | $120.95 | 586 144 |
| 2022-12-28 | $113.73 | $117.43 | $113.52 | $116.67 | 248 744 |
| 2022-12-27 | $119.99 | $119.99 | $114.11 | $114.47 | 114 889 |
| 2022-12-23 | $119.99 | $119.99 | $116.30 | $119.09 | 222 593 |
| 2022-12-22 | $119.13 | $120.52 | $118.02 | $119.20 | 174 572 |
| 2022-12-21 | $118.75 | $121.12 | $118.75 | $120.71 | 243 664 |
| 2022-12-20 | $116.50 | $120.93 | $116.50 | $119.01 | 241 220 |
| 2022-12-19 | $118.33 | $118.36 | $113.79 | $116.26 | 418 342 |
| 2022-12-16 | $118.38 | $120.41 | $116.77 | $118.60 | 249 900 |
| 2022-12-15 | $120.61 | $121.32 | $118.91 | $119.01 | 246 015 |
| 2022-12-14 | $122.00 | $122.99 | $119.21 | $121.47 | 421 556 |
| 2022-12-13 | $123.98 | $124.66 | $121.65 | $122.81 | 442 575 |
| 2022-12-12 | $117.56 | $122.66 | $115.21 | $122.53 | 3 036 581 |
| 2022-12-09 | $119.22 | $119.84 | $116.48 | $117.07 | 223 017 |
| 2022-12-08 | $121.53 | $121.86 | $118.97 | $119.45 | 364 376 |
| 2022-12-07 | $121.15 | $122.56 | $118.51 | $119.98 | 306 082 |
| 2022-12-06 | $119.46 | $122.22 | $117.86 | $120.66 | 263 426 |
| 2022-12-05 | $125.14 | $125.97 | $119.00 | $119.42 | 1 142 383 |
| 2022-12-02 | $120.55 | $127.12 | $119.41 | $125.39 | 2 355 034 |
| 2022-12-01 | $123.00 | $123.50 | $120.73 | $121.75 | 608 103 |
| 2022-11-30 | $119.90 | $124.18 | $119.80 | $123.06 | 780 835 |
| 2022-11-29 | $120.72 | $120.74 | $116.62 | $118.42 | 147 153 |
| 2022-11-28 | $115.82 | $120.23 | $115.50 | $119.50 | 358 015 |
| 2022-11-25 | $118.86 | $120.37 | $115.30 | $115.94 | 193 296 |
| 2022-11-23 | $120.61 | $122.80 | $116.07 | $118.84 | 461 100 |
| 2022-11-22 | $117.66 | $120.20 | $116.63 | $120.09 | 199 239 |
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops Tra... ASND Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
